Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

This research study is for people recently diagnosed with non-small cell lung cancer that has spread to other parts of the body. Doctors are trying to find the best ways to treat this type of cancer. Currently, many people receive a medicine called pembrolizumab through a special drip into their vein. This study is testing a new way to give pembrolizumab: as an injection just under the skin. The main goal is to understand how well the injected version works in the body compared to the version given through a drip. They want to learn how much medicine gets into the body and how long it stays there when given in these different ways.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Einschreibeziel
67
Starten
21. Nov. 2024
Geschätzte Fertigstellung
17 Apr 2027

Worum geht es in dieser Studie?

This study is looking for new and easier ways to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC), especially when it has spread to other parts of the body. This is often called metastatic cancer. Finding new and gentler treatment options is a big focus for doctors and researchers.

One of the current treatments is a medicine called pembrolizumab. It's a type of immunotherapy, which helps your body's own immune system fight the cancer. Usually, this medicine is given through a needle into a vein in your arm, like a drip, which is called an intravenous (IV) infusion. This study is testing if an alternative way of giving the medicine, through a simple injection under the skin (called a subcutaneous or SC injection), works similarly.

The main idea behind this study is to compare how pembrolizumab acts in your body when given as an IV drip versus a skin injection. Researchers will look at things like how quickly the medicine gets into your system and how long it stays there with each method. This information helps them understand if the new injection method could be a good and convenient option for patients in the future.

Wichtige Erkenntnisse

  • This study is for advanced non-small cell lung cancer.
  • It's comparing two ways to give the medicine pembrolizumab: IV drip vs. under-skin injection.
  • The aim is to understand how the new injection works in the body.
  • Participation involves regular clinic visits for treatment and tests.
  • Sie können die Teilnahme jederzeit beenden.
  • The study helps improve future lung cancer treatments.

Wer könnte berechtigt sein?

To be part of this study, you would generally need to have a confirmed diagnosis of non-small cell lung cancer that has spread to other parts of your body. Doctors would also need to see that your cancer can be measured, often through scans, so they can track how you respond to treatment.

There are also reasons why you might not be able to join. For example, if you have a different type of lung cancer called small cell lung cancer, you wouldn't be suitable for this specific study. Also, if you've already had other treatments for your metastatic non-small cell lung cancer, or if you have certain other serious health conditions like active autoimmune diseases or some types of lung problems, this study might not be right for you. They also can't include people with certain active infections or cancer that has spread to the brain and is causing problems.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have non-small cell lung cancer that has spread.
  2. My cancer was recently diagnosed as metastatic.
  3. I haven't had other treatments for my widespread lung cancer yet.
  4. I do not have other serious active medical conditions, like some severe autoimmune diseases or certain lung problems.
  5. My cancer can be seen and measured on scans.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you might receive pembrolizumab either through a drip into your arm or as an injection under your skin, depending on which group you are in. You would need to attend regular clinic visits for this treatment and to have various tests, such as blood tests and scans, to see how your body is reacting to the medicine and how your cancer is responding. The exact number of visits and tests will be explained in detail by the study team. You would be followed closely by the medical team throughout the study and potentially for some time after your treatment finishes to monitor your health.

Potenzielle Risiken und Vorteile

Taking part in any medical study has potential benefits and risks. A potential benefit could be access to a new way of receiving treatment that might be more convenient, or the chance to help doctors learn more about better lung cancer care for everyone. However, like all medicines, pembrolizumab can have side effects, and the new injection method may have unique effects. The study team will explain all known potential side effects and risks to you in detail. You are always in control of your decision and can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (67)

  • Providence Medical Foundation ( Site 0117)
    Verifizierte Postleitzahl
    Fullerton, Vereinigte Staaten
  • Illinois Cancer Care ( Site 0101)
    Verifizierte Postleitzahl
    Peoria, United States
  • Montefiore Medical Center ( Site 0104)
    Verifizierte Postleitzahl
    The Bronx, United States
  • University of Cincinnati Medical Center ( Site 0112)
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten
  • Beijing Peking Union Medical College Hospital ( Site 5000)
    Verifizierte Postleitzahl
    Peking, China
  • Chongqing University Three Gorges Hospital ( Site 5018)
    Verifizierte Postleitzahl
    Chongqing, China
  • Fujian Province Cancer Hospital ( Site 5007)
    Verifizierte Postleitzahl
    Fuzhou, China
  • The First Affiliated hospital of Xiamen University ( Site 5008)
    Verifizierte Postleitzahl
    Xiamen, China
  • The first affiliated hospital, Sun Yat-Sen university ( Site 5011)
    Verifizierte Postleitzahl
    Guangzhou, China
  • Southern Medical University Nanfang Hospital ( Site 5003)
    Verifizierte Postleitzahl
    Guangzhou, China
  • Huizhou Central People's Hospital ( Site 5004)
    Verifizierte Postleitzahl
    Huizhou, China
  • Jiangmen Center Hospital ( Site 5001)
    Verifizierte Postleitzahl
    Jiangmen, China

Häufige Fragen

Was ist das Hauptziel dieser Studie?

The main goal is to compare two ways of giving the lung cancer medicine pembrolizumab: through a drip in your arm or as an injection under the skin.

What kind of lung cancer is this study for?

It's for people recently diagnosed with non-small cell lung cancer that has spread to other parts of the body.

Was ist Pembrolizumab?

It's a type of immunotherapy medicine that helps your immune system fight cancer.

Will I definitely get the new injection?

You might get the injection or the usual drip; it depends on which group you are assigned to as part of the study.

Kann ich die Teilnahme an der Studie beenden, wenn ich meine Meinung ändere?

Yes, you can leave the study at any time without it affecting your future medical care.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.